Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 10/20 | 0.51 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16462935 | 0.89 | CAPN1 (0.47) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL17106928 | 0.87 | CTSD (0.54) | CTSBF2HDAC8CTSLCTSS | |
| SCHEMBL17106927 | 0.87 | CTSD (0.54) | CTSBF2HDAC8CTSLCTSS | |
| SCHEMBL17106929 | 0.87 | CTSD (0.54) | CTSBF2HDAC8CTSLCTSS | |
| SCHEMBL17106926 | 0.85 | CYP3A4 (0.56) | CTSBF2HDAC8CTSLCTSS | |
| SCHEMBL16464284 | 0.85 | CYP3A4 (0.56) | CTSBF2HDAC8CTSLCTSS | |
| SCHEMBL16482790 | 0.85 | CAPN1 (0.58) | CAPN1CTSBF2HDAC8CTSL | |
| SCHEMBL16463253 | 0.85 | CAPN1 (0.49) | CAPN1CTSD | |
| SCHEMBL17106905 | 0.85 | ATM (0.54) | CTSBHDAC8CTSLCTSSCTSK | |
| SCHEMBL16463321 | 0.85 | ATM (0.54) | CTSBHDAC8CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | claimed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | CAPN1 566/4885CTSB 255/4885F2 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.